Trejeeve (Tre) Martyn, Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists, we highlight how these therapies are reshaping care across the cardiometabolic spectrum, including obesity, ASCVD, HFpEF, CKD, MASLD/MASH, and obstructive sleep apnea
Some patients may become biochemically hyperthyroid (suppressed TSH, elevated free T4) if their levothyroxine dose is not adjusted downward in response to weight loss
Studies show that stopping GLP-1 therapy can lead to weight regain, which is why we focus on sustainable lifestyle changes alongside medication
Many clinics provide certificates of analysis showing purity testing results, typically demonstrating 98%+ purity levels for peptides like semaglutide and tirzepatide